San Diego, CA, April 22, 2016 --(PR.com
)-- Michael Seaman, Assistant Professor of Medicine at the Center for Virology and Vaccine Research with Harvard Medical School, will give a keynote presentation on “Choosing Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Infection” at GTCbio’s Antiviral Drugs Research & Development Conference on June 1-2, 2016 in San Diego, CA.
The identification of a new generation of potent broadly neutralizing HIV-1 antibodies (bnAbs) has generated substantial interest in their potential use for the prevention and/or treatment of HIV-1 infection. While combinations of bnAbs targeting distinct epitopes on the viral envelope (Env) will likely be required to overcome the extraordinary diversity of HIV-1, a key outstanding question is which bnAbs, and how many, will be needed to achieve optimal clinical benefit. This presentation will describe a study in which the neutralizing activity of 15 bnAbs targeting four distinct epitopes of Env was assessed against a panel of 200 early/acute HIV-1 clade C viruses. A mathematical model was developed to perform a comprehensive and systematic comparison of the predicted neutralizing activity of over 1,600 possible double, triple, and quadruple bnAb combinations. The most promising bnAb combinations were identified based not only on breadth and potency of neutralization, but also other relevant measures, such as the extent of complete neutralization and instantaneous inhibitory potential (IIP). Given the tremendous resources required to take each single bnAb forward into clinical testing, this presentation outlines important parameters that can inform the selection of bnAbs with the best indicators of success for clinical development.
Key questions that will be addressed include:
•Which bnAbs targeting each major epitope exhibit the greatest breadth and potency?
•What in vitro measures and models can be used for identifying optimal bnAb combinations?
•What are the optimal 2-, 3-, or 4-bnAb combinations and how do they compare in terms of optimal potency, breadth, complete neutralization, and active coverage?
Michael Seaman received his Ph.D. in Immunology from the University of Texas Southwestern Medical Center in 2000. He did his post-doctoral research training at Harvard Medical School where he studied the use of cytokine adjuvants for augmenting HIV vaccine-elicited T cell responses. Since 2006, Dr. Seaman has directed the Collaboration for AIDS Vaccine Discovery (CAVD) Pre-Clinical Neutralizing Antibody Core Laboratory which is supported by the Bill and Melinda Gates Foundation. A major focus of his laboratory research involves studying neutralizing antibody responses directed against HIV-1, SHIV, or SIV in the setting of vaccination and/or infection. In particular, his laboratory has been extensively involved in the characterization of a new generation of potent broadly neutralizing monoclonal antibodies that are actively being investigated for their potential use in the prevention and/or treatment of HIV-1 infection.
The 5th Antiviral Drugs Research & Development Conference brings together a mix of academic and industry authoritative experts from leading affiliations (Harvard Medical School, The Scripps Research Institute, Arbutus, Sanofi Pasteur, U.S. Government Military HIV Research Program (MHRP), etc.) to cover many current and relevant aspects of new inhibitory mechanisms, longer acting drugs, and strategies en route for cures in HIV, RSV, Hepatitis B/C, Influenza, etc.
This conference is also part of their larger Infectious Diseases World Summit, which consists of 4 total conferences:
14th Vaccines Research & Development
13th Anti-Infectives Partnering & Deal-Making
5th Antiviral Drugs Research & Development
2nd Bugs & Drugs: Antibacterial Drug Discovery
For more information, please visit the website: http://www.gtcbio.com/antiviraldrugs
635 W. Foothill Blvd
Monrovia, CA 91016
Phone: (626) 256-6405
Fax: (626) 466-4433